Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 28

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 28
---
, without limitation, those specifically
addressed under the heading “Risk Factors” contained in this prospectus, the accompanying prospectus and any related free
writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus and the
accompanying prospectus, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as any amendments
thereto reflected in subsequent filings with the SEC. Readers are urged not to place undue reliance on these forward-looking statements,
which speak only as of the date made. We file reports with the SEC, and our electronic filings with the SEC (including our Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and any amendments to these reports) are available free
of charge on the SEC’s website at http://www.sec.gov.

We undertake no obligation
to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this
prospectus, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the
entirety of this prospectus, the accompanying prospectus and any related free writing prospectus, and the documents incorporated by reference
into this prospectus and the accompanying prospectus, which disclosures are designed to advise interested parties of the risks and factors
that may affect our business, financial condition, results of operations and prospects.

<div align='center'>9

USE OF PROCEEDS</div>

We are filing the registration
statement of which this prospectus forms a part to permit the holders of the Shares of our Common Stock described in the section entitled
“Selling Stockholders” to resell such Shares. We are not selling any securities under this prospectus and will not receive
any of the proceeds from the sale of Shares by the selling stockholders. We will likely only receive nominal proceeds of $0.0001 per share
upon the cash exercise of the Pre-Funded Warrants. Though we would receive the proceeds for the cash exercise of the Series A Warrants
per their terms, we are unlikely to receive any cash proceeds from the exercise of the Series A Warrants as the Series A Warrants may
be exercised following stockholder approval on a zero exercise price basis where the holder will be eligible to receive, for each share
of Common Stock issuable upon exercise of the Series A Warrant, three shares